Summary: BLS Polymers Limited filed its final prospectus with the Registrar of Companies, as recorded on SEBI’s website on 30 October 2026, following the closure of its initial public offering (IPO) on 29 October 2026. The book-built IPO, which opened on 27 October 2026, comprised a fresh issue of up to 1.70 crore equity shares at a final issue price of ₹150 per share, aggregating up to ₹255 crore, without any offer-for-sale component. The minimum application lot was 100 shares, requiring an investment of ₹15,000. The company, engaged in manufacturing customised polymer compounds for the power, telecommunications, railways, water distribution and oil and gas sectors, proposes to utilise the proceeds primarily for expanding its Goa manufacturing facility, meeting working capital requirements and general corporate purposes. According to its draft prospectus, revenue from operations increased to ₹328.44 crore in FY 2024-25 from ₹296.36 crore in FY 2023-24, while annual profit rose to ₹21.14 crore from ₹7.52 crore. However, significant risks include customer concentration, with the top ten customers contributing 64.44% of FY 2024-25 revenue, substantial raw-material costs, dependence on power and telecommunications customers, and execution risks associated with capacity expansion. Following the closure of bidding, applicants must monitor allotment, ASBA fund unblocking, demat credit and listing through official exchange and registrar channels. The proposed listing on NSE and BSE remains subject to completion of the prescribed procedures and exchange approvals. Investors should assess the company’s financial performance, utilisation of IPO proceeds, operational risks and applicable capital gains tax implications without relying on unofficial grey-market premiums or speculative listing-price predictions.
- What changed when BLS Polymers filed its final prospectus
- From DRHP to prospectus: documents should not be mixed
- The DRHP began regulatory review but was not an open invitation
- Applicants should retain the document applicable to their decision
- What BLS Polymers does and where revenue concentration appears
- How the ₹255 crore fresh issue is intended to be used
- Goa manufacturing expansion
- Working capital and general corporate purposes
- Risk factors that remain relevant after allotment
- Customer and end-industry concentration
- Raw-material price, availability and pass-through risk
- Expansion and utilisation risk
- Listing, liquidity and price risk
- Allotment, unblocking, demat credit and grievance route
- Tax treatment for a successful allottee
- Frequently Asked Questions
- 1. Is the BLS Polymers offer still open for bidding?
- 2. What is the finalized issue price and size?
- 3. Does SEBI’s filing mean SEBI recommends the shares?
- 4. Where should an applicant check allotment status?
- 5. What is the minimum application value?
- 6. Are the IPO proceeds paid to selling shareholders?
- 7. Is a gain on a listing-day sale tax-free?
- 8. Is the proposed 3 November listing date guaranteed?
- Key Takeaways
What changed when BLS Polymers filed its final prospectus
BLS Polymers Limited’s book-built initial public offering opened on 27 October 2026 and closed on 29 October 2026. On 30 October 2026, the Securities and Exchange Board of India filing page classified the company’s prospectus under final offer documents filed with the Registrar of Companies. That is the material development covered here: the offer has moved beyond the red herring stage, the bidding window has closed, and the final prospectus records the issue price and finalized offer particulars. This article does not use grey-market premiums or predict the listing price.
The final issue price is ₹150 per equity share, including a ₹140 premium over the ₹10 face value. The issue comprises up to 1,70,00,000 new equity shares and therefore aggregates up to ₹255 crore at that price. It is a fresh issue; there is no offer for sale. The company receives the gross issue proceeds before issue expenses, and its proposed deployment—not a selling shareholder’s exit—is the central use-of-funds question. The stock-exchange symbol shown on NSE’s issue page is BLSPOLY, and the designated stock exchange is NSE, with proposed listing on NSE and BSE.
| Final offer term | Verified detail | Editorial significance |
|---|---|---|
| Issuer | BLS Polymers Limited | The issuer is a polymer-compound manufacturer; it should not be confused with similarly named listed entities. |
| Filing stage | Final prospectus filed with RoC; SEBI filing dated 30 October 2026 | The DRHP and RHP were earlier lifecycle documents; post-close facts should be taken from the prospectus and exchange notices. |
| Issue structure | Fresh issue of up to 1,70,00,000 equity shares; no OFS | All gross proceeds arise from new shares, subject to issue expenses and the stated objects. |
| Issue price and size | ₹150 per share; up to ₹255 crore | This is the finalized price, not merely the upper end of the earlier band. |
| Face value and bid lot | ₹10 face value; 100 shares and multiples of 100 | A 100-share application at the issue price represents ₹15,000 blocked through ASBA/UPI, subject to application validity. |
| Issue period | 27–29 October 2026 | No fresh bid can be submitted after close; applicants move to allotment, unblock/refund and credit steps. |
| Intermediaries | BRLM: Unistone Capital Private Limited; registrar: KFin Technologies Limited | Allotment and application-status checks should use official exchange or registrar channels. |
From DRHP to prospectus: documents should not be mixed
The DRHP began regulatory review but was not an open invitation
The draft red herring prospectus disclosed the proposed fresh issue, business, objects, restated financial statements and risk factors before price and issue dates were final. A DRHP is neither a SEBI investment approval nor a live offer. The red herring prospectus dated 17 October 2026 then supported the launch, and the 26 October addendum carried the ₹142–₹150 price band and related updates. After the bid period, the final prospectus filed with the RoC completes the offer-document sequence and records the finalized price.
Applicants should retain the document applicable to their decision
A change introduced by an addendum or prospectus can supersede a DRHP statement. An applicant reviewing an allotment, payment block or future disclosure should therefore retain the application number and consult the RHP, addendum, final prospectus, basis-of-allotment notice and exchange trading notice as applicable. The presence of a filing on SEBI’s website verifies regulatory filing, not commercial success or future market performance.
What BLS Polymers does and where revenue concentration appears
The offer documents describe BLS Polymers as a manufacturer of multiple grades of custom-formulated polymer compounds used in critical industries, including telecommunication, power, railways, water, and oil and gas distribution. Its Goa manufacturing facility is central to the proposed capital-expenditure object. The company also depends heavily on wire and cable polymer compounds and on a concentrated customer base, so an investor should connect revenue growth with concentration, raw-material costs and the ability to pass through price changes.
The DRHP reported revenue from operations of ₹32,843.59 lakh in Fiscal 2025, ₹29,635.83 lakh in Fiscal 2024 and ₹31,461.61 lakh in Fiscal 2023. Profit for the year was ₹2,113.60 lakh, ₹752.20 lakh and ₹624.98 lakh respectively. Those figures show a sharp Fiscal 2025 profit increase, but they should not be extrapolated mechanically. The same document reported that the top ten customers contributed 64.44% of Fiscal 2025 revenue, while raw-material consumption represented 80.85% of revenue from operations. Power and telecommunication customers accounted for 81.59% of Fiscal 2025 revenue.
| Restated metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue from operations | ₹32,843.59 lakh | ₹29,635.83 lakh | ₹31,461.61 lakh |
| Profit for the year | ₹2,113.60 lakh | ₹752.20 lakh | ₹624.98 lakh |
| Top ten customers / revenue | 64.44% | 50.52% | 51.02% |
| Raw material consumed / revenue | 80.85% | 83.90% | 85.04% |
| Power & telecom / revenue | 81.59% | 80.49% | 94.32% |
The table uses restated figures and ratios disclosed in the offer document available through NSE. They are historical measures, not forecasts. A reader should use the final prospectus for the complete accounting policies, notes, related-party information, contingent liabilities, cash flows and any later period included after the original DRHP.
How the ₹255 crore fresh issue is intended to be used
Goa manufacturing expansion
The DRHP allocated ₹6,984.32 lakh of net proceeds to expand the existing Goa manufacturing facility by increasing capacity for specified existing products. Capital expenditure can improve capacity but creates execution risks: equipment procurement, installation, regulatory clearances, commissioning, customer qualification and utilisation may not follow the original schedule. The final prospectus should be checked for the updated deployment schedule and whether any amount changed after the final issue price was determined.
Working capital and general corporate purposes
The draft objects allocated ₹7,500 lakh to working-capital requirements. The residual amount, after issue expenses and the specified objects, was earmarked for general corporate purposes within the regulatory ceiling. Working-capital funding supports inventory and receivables but does not by itself ensure profitable sales or collection. The DRHP showed Fiscal 2025 inventory and receivable holding periods of 65 and 76 days respectively, making conversion of funded working capital into cash a continuing monitoring point.
| Object disclosed in DRHP | Draft amount | What should be monitored after listing |
|---|---|---|
| Goa facility capacity expansion | ₹6,984.32 lakh | Orders, installation, commissioning, capacity addition and actual utilisation |
| Working-capital requirements | ₹7,500 lakh | Inventory days, receivable days, customer terms and operating cash flow |
| General corporate purposes | Residual within applicable cap | Board-approved uses and monitoring-agency disclosures |
| Issue expenses | Deducted before net proceeds | Final expenses and resulting net amount available for the objects |
Risk factors that remain relevant after allotment
Customer and end-industry concentration
A 64.44% contribution from the top ten customers in Fiscal 2025 means loss of a major account, reduced orders, pricing disputes or customer plant shutdowns could materially affect results. Power and telecommunication exposure is also high. Diversification language should be tested against actual revenue mix in later financial results rather than assumed from the number of industries named in the business description.
Raw-material price, availability and pass-through risk
Raw materials consumed were more than four-fifths of Fiscal 2025 revenue from operations. Polymer inputs can be affected by petrochemical prices, currency movements, supplier availability and quality. If sales contracts do not permit timely cost pass-through, margins can compress even when volumes rise. The percentage declined across the three reported years, but that historical trend is not a promise.
Expansion and utilisation risk
Fresh capital does not remove commissioning or demand risk. Delays can raise costs; low utilisation can depress returns on capital; and product qualification can postpone commercial sales. Investors should compare actual utilisation disclosures with the prospectus schedule rather than using the intended capacity as though it were operational.
Listing, liquidity and price risk
This is the company’s first public issue. There was no established public market before listing. The offer price does not guarantee an active market, liquidity, price stability or gains. Listing can occur below the issue price, and later prices can react to financial results, supply-demand conditions, lock-in expiries, sector cycles and broader markets. Grey-market quotations are unofficial and are deliberately excluded from this article.
Allotment, unblocking, demat credit and grievance route
After closure, the registrar and designated stock exchange finalise the basis of allotment under the issue framework. A valid application may receive full, partial or no allotment. ASBA blocks funds rather than transferring them at application; the amount corresponding to allotted shares is debited and the balance is unblocked. UPI applications depend on successful mandate acceptance and application validity. Applicants should check official status using the PAN and application details on the registrar or exchange portal and should not share OTPs or payment credentials with unsolicited callers.
- First verify the application number, PAN, demat beneficiary details and bank/UPI mandate status.
- Check allotment only on KFin Technologies, NSE or BSE official facilities when the issuer is available there.
- If the block remains after the official unblock date, contact the SCSB or bank with the application and mandate reference.
- For allotment or registrar-data discrepancies, raise a written ticket with KFin Technologies and preserve the acknowledgement.
- Escalate unresolved securities-market complaints through SEBI SCORES and use the exchange grievance channel where relevant.
- Confirm demat credit and the separate exchange trading notice before attempting to sell; a tentative listing date is not itself proof that trading has begun.
Tax treatment for a successful allottee
Receipt of shares on allotment at the issue price does not ordinarily create a capital gain merely because the securities enter the demat account. Tax consequences generally arise on a later transfer. For Tax Year 2026–27, the Income-tax Act, 2025 applies. Subject to statutory conditions including recognised-exchange transfer and securities transaction tax, section 196 covers specified short-term listed-equity gains at 20%, while qualifying long-term listed-equity gains under the applicable provisions are taxed at 12.5% above the statutory threshold. Holding-period classification, cost, brokerage, exchange charges, STT, set-off rules, non-resident provisions and any grandfathering or corporate action must be checked for the actual transaction. STT is not generally deducted as a capital-gains expense where the statute prohibits it.
An investor should retain the contract note, demat statement, allotment advice, bank debit record and expense ledger. A listing-day sale is not tax-free simply because the shares came through an IPO. Business-income treatment can apply where facts show trading activity rather than investment, and non-residents may have treaty, withholding and foreign-exchange questions requiring professional review.
Frequently Asked Questions
1. Is the BLS Polymers offer still open for bidding?
No. NSE’s issue page shows a 27–29 October 2026 issue period. The SEBI filing dated 30 October is the final prospectus stage after closure, not an extension of bidding.
2. What is the finalized issue price and size?
The final issue price is ₹150 per equity share. With up to 1,70,00,000 fresh shares, the issue aggregates up to ₹255 crore. There is no offer-for-sale component.
3. Does SEBI’s filing mean SEBI recommends the shares?
No. Filing and disclosure review do not amount to an investment recommendation, guarantee of accuracy in every commercial outcome or assurance of listing performance.
4. Where should an applicant check allotment status?
Use the official KFin Technologies, NSE or BSE facility once the issuer is enabled. Avoid unofficial pages that request passwords, OTPs, UPI PINs or advance fees.
5. What is the minimum application value?
The bid lot was 100 shares. At the ₹150 issue price, one lot represents ₹15,000. Application validity and category limits still apply.
6. Are the IPO proceeds paid to selling shareholders?
No. The issue is a fresh issue without an OFS. Gross proceeds go to the issuer, subject to issue expenses and deployment under the disclosed objects.
7. Is a gain on a listing-day sale tax-free?
No. A listing-day sale can create short-term capital gain or loss, subject to the taxpayer’s facts and the Income-tax Act, 2025. The special listed-equity rate and STT conditions should be checked with the contract note.
8. Is the proposed 3 November listing date guaranteed?
No. The offer timetable is subject to completion of allotment, funds, demat credit and exchange approvals. Trading should be treated as live only after the relevant exchange notice and market availability.
Key Takeaways
- SEBI recorded BLS Polymers’ final prospectus on 30 October 2026 after the 27–29 October bid period.
- The finalized ₹150 price makes the fresh issue up to ₹255 crore for 1,70,00,000 new shares; there is no OFS.
- The disclosed objects focus on Goa capacity expansion, working capital and permitted general corporate purposes.
- Historical growth must be read alongside customer concentration, raw-material intensity, end-industry concentration and expansion execution risk.
- Applicants should use official registrar, exchange and bank channels for allotment, unblock, demat credit and complaints.
- This article excludes GMP and makes no listing-price or return prediction.
******
Disclaimer: This article is an educational, current-date summary of the BLS Polymers Limited public issue and the material filing of its final prospectus, prepared from SEBI’s public-issue page and prospectus link, NSE’s issue-information page, the issuer’s offer documents available through the exchanges, and Income Tax Department materials checked on 31 October 2026. It is not an offer document, application advice, investment recommendation, valuation opinion, allotment confirmation, listing forecast, tax return position or assurance of liquidity or profit. A DRHP is a draft disclosure document and not an open offer or SEBI approval; the RHP, addendum, final prospectus, basis of allotment, registrar records and exchange trading notices serve different stages and may update earlier information. Issue-price, application, allotment, bank-block, demat and tax outcomes depend on the applicant’s category, valid bid, PAN, bank mandate, depository details, final basis of allotment, exchange actions and later law. Historical revenue and profit, concentration ratios, stated objects and intended capacity expenditure do not predict future performance or guarantee deployment on schedule. Equity shares can list or trade below the issue price, and investors can lose part or all of their capital. Grey-market premiums and unofficial subscription claims are excluded because they are neither regulated issue terms nor reliable forecasts. Tax rates described are subject to statutory conditions, holding period, STT, taxpayer status, transaction character, treaty position and future amendments. Readers should examine the complete final prospectus and official notices and consult a SEBI-registered adviser, chartered accountant, tax adviser or lawyer for their own circumstances. TaxGuru accepts no responsibility or liability for an application, allotment, bank block, sale, tax filing, investment decision, missed deadline, market loss, data mismatch, later correction or reliance on this summary.
